Selective estrogen receptors modulators in the prevention and treatment of postmenopausal osteoporosis

Endocrinology and Metabolism Clinics of North America

Volumn 32, Issue 1, 2003, Pages 219-232

  Fontana, Aurelie ^a   Delmas, Pierre D ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BAZEDOXIFENE; CENTCHROMAN; CHOLESTEROL; DROLOXIFENE; ESTRADIOL; IDOXIFENE; NORETHISTERONE; OSTEOCALCIN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG;

BONE METABOLISM; BONE TURNOVER; BREAST CANCER; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CATARACT; CHOLESTEROL BLOOD LEVEL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG MECHANISM; ENDOMETRIUM CARCINOMA; FEMALE; FLU LIKE SYNDROME; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; ISCHEMIC HEART DISEASE; LEG CRAMP; LUNG EMBOLISM; ORCHIECTOMY; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; URINE INCONTINENCE; UTERUS PROLAPSE; VAGINA DISCHARGE; VEIN THROMBOSIS; VERTEBRA FRACTURE;

GOES;

EID: 0037299460     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8529(02)00057-9     Document Type: Review

References (41)

1. Felson DT, Zhang Y, Hannan MT, et al. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993;329:1141-6.
2. Collaborative Group on Hormonal Therapy in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350:1047-59.
3. Chen CH, Weiss NS, Newcomb P, et al. Hormone replacement therapy in relation to breast cancer. JAMA 2002;287:734-41.
4. Sato M, McClintock G, Kim J, et al. Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats. J Bone Miner Res 1994;9:715-24.
5. Black LJ, Sato M, Rowley ER, et al. Raloxifene (LY 139481 HCL) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994;93:63-9.
6. Turner CH, Sato M, Bryant HU. Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinol 1994;135:2001-5.
7. Bourrin S, Ammann P, Bonjour JP, et al. Recovery of proximal tibia bone mineral density and strength, but not cancellous bone architecture, after long-term bisphosphonate or selective estrogen receptor modulator therapy in aged rats. Bone 2002;30:195-200.
8. Kenny AM, Prestwood KM, Pilbeam CC, et al. The short-term effects of tamoxifen on bone turnover in older women. J Clin Endocrinol Metab 1995;80:3287-91.
9. Marttunen MB, Hietanen P, Titinen A, et al. Effects of tamoxifen and toremifene on urinary excretion of pyridinoline and deoxypyridinoline and bone density in postmenopausal patients with breast cancer. Calcif Tissue Int 1999;65:365-8.
10. Marttunen MB, Hietanen P, Titinen A, et al. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab 1998;83:1158-62.
11. Draper MW, Flowers DE, Huster WJ, et al. A controlled trial of raloxifene (LY 139481)HCI: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996;11:835-42.
12. Prestwood KM, Gunness M, Muchmore DB, et al. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab 2000;85:2197-202.
13. Delmas PD, Bjarnasson NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterolconcentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-7.
14. Johnston CC, Bjarnasson NH, Cohen FJ, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women. Arch Intern Med 2000;160:3444-50.
15. Lufkin EG, Whitaker MD, Nickelson T, et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 1998;13:1747-54.
16. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 1999;282:637-45.
17. Powles TJ, Hardy JR, Ashley SE, et al. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 1989;60:126-33.
18. Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual energy X-Ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996;14:78-84.
19. Turken S, Siris E, Seldin D, et al. Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst 1989;81:1086-8.
20. Kristensen B, Ejlertsen B, Dalgaard P, et al. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol 1994;12:992-7.
21. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-6.
22. Love RR, Barden HS, Mazess RB, et al. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 1994;154:2595-8.
23. Delmas PD, Balena R, Confavreux E, et al. Bisphosphonate Risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double blind, placebo-controlled study. J Clin Oncol 1997;15:955-62.
24. Chang J, Powles TJ, Ashley SE, et al. The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study. Ann Oncol 1996;7:671-5.
25. Grey AB, Stapleton JP, Evans MC, et al. The effect of antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am J Med 1995;99:636-41.
26. Meunier PJ, Vignot E, Garnero P, et al. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Osteoporos Int 1999;10:330-6.
27. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 1998;90:1371-88.
28. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609-17.
29. Sarkar S, Mitlak B, Wong M, et al. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002;17:1-10.
30. McDonald CC, Alexander FE, Whyte BW, et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial. The Scottish Cancer Trials Breast Group. BMJ 1995;311:977-80.
31. Wash BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998;279:1445-51.
32. Mosca L, Barret-Connor E, Wenger NK, et al. Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am J Cardiol 2001;88:392-5.
33. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women. JAMA 2002;287:847-57.
34. Cummings SR, Eckert S, Kruegor KA, et al. The effect of raloxifene on the risk of breast cancer in postmenopausal women. JAMA 1999;281:2189-97.
35. Davies GC, Huster WJ, Lu Y, et al. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 1999;93:558-65.
36. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339:1609-1618.
37. Cauley JA, Norton L, Lippman LE, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001;65:125-34.
38. Yaffe K, Krueger K, Sarkar S, et al. Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med 2001;344:1207-13.
39. Alexandersen P, Riis BJ, Stakkestad JA, et al. Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy. J Clin Endocrinol Metab 2001;86:755-60.
40. Riggs B, Khosla S, Melton LJ. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 1998;13:763-73.
41. Ke QZ, Qi H, Crawford DT, et al. Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat. Endocrinology 2000;141:1338-44.